Optibrium has launched Cerella, an AI software platform for drug discovery that delivers active learning using advanced deep learning methods. Cerella uses the Alchemite algorithm, developed by Optibrium technology partner Intellegens, which aims to reduce costs and improve cycle times while targeting high-quality compounds.
Cerella’s architecture combines on-premises deployment with cloud computing, providing both data security and scalability. Sensitive information is processed on-premises, while the cloud-based components work only with encrypted and anonymised data, enabling scaling from individual project data sets to corporate compound repositories containing millions of compounds.
By connecting directly with a corporate compound database, Cerella automatically updates models using the latest data to ensure the predictions and analyses are up to date.
Optibrium has done peer-reviewed studies which it says demonstrate Cerella's reductions in cost and time of discovery cycles over conventional modelling methods.
Matthew Segall, Optibrium’s CEO, commented on the launch: “Our Augmented Chemistry platform continues to amaze our collaborators with the unprecedented outcomes it delivers. We are proud to reach this new milestone of launching Cerella, enabling us to put our technologies directly into the hands of our customers.”